← Oncology Approval Tracker

FDA DECISION ·

Ukoniq

umbralisib · TG Therapeutics

Accelerated approvalNew therapyMarginal zone lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Indication withdrawn on May 31, 2022

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with relapsed or refractory marginal zone lymphoma after at least one anti-CD20-based regimen. FDA records list withdrawal of this indication on May 31, 2022.

LAMPGEN ANALYSIS

Why it matters

The accelerated decision was specific to an anti-CD20-exposed population and was later withdrawn.

What research teams should watch

Keep the initial approval and withdrawal dates linked in longitudinal analyses of available regimens.

PRIMARY RECORDS

Sources